Acumen Pharmaceuticals, INC Form 4 insider transactions

Acumen Pharmaceuticals' CFO and Chief Business Officer, Matt Zuga, sold a total of 14,905 shares of common stock in early January 2026 to cover tax withholding obligations related to RSU vesting.

Acumen Pharmaceuticals' Chief Medical Officer, Eric Siemers, sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Acumen Pharmaceuticals CEO Daniel O'Connell sold common stock totaling 47,506 shares across three transactions in early January 2026 to cover tax withholding obligations.

Acumen Pharmaceuticals' Chief Legal Officer, Derek M. Meisner, sold a total of 26,568 shares of common stock in early January 2026 through pre-arranged Rule 10b5-1 trading plans.

Acumen Pharmaceuticals' Chief Operating Officer, Russell Barton, sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Acumen Pharmaceuticals, Inc. Director George Golumbeski was granted 50,000 stock options with an exercise price of $1.90, vesting over three years.

RA Capital Management, a significant shareholder and director of Acumen Pharmaceuticals, reported the grant of restricted stock units and stock options to director Laura Stoppel as part of the company's non-employee director compensation policy.

Acumen Pharmaceuticals, Inc. Director Laura Stoppel was granted 12,800 restricted stock units and options to purchase 19,500 shares of common stock, though she disclaims personal beneficial ownership as these are held for the benefit of RA Capital Management funds.

Acumen Pharmaceuticals, Inc. Director John A. Stalfort III was granted 12,800 restricted stock units and options to purchase 19,500 shares of common stock, aligning his interests with shareholder value.

Acumen Pharmaceuticals, Inc. Director Nathan B. Fountain was granted 12,800 restricted stock units and 19,500 stock options, aligning his interests with shareholders.

Acumen Pharmaceuticals, Inc. Director Kimberlee C. Drapkin was granted 12,800 restricted stock units and 19,500 stock options on June 4, 2025, as part of her compensation.

Acumen Pharmaceuticals, Inc. Director Jeffrey L. Ives was granted 12,800 restricted stock units and options to purchase 19,500 shares of common stock on June 4, 2025, as part of his compensation package.

Acumen Pharmaceuticals, Inc. Director Derrell Porter was granted 12,800 restricted stock units and 19,500 stock options, aligning his interests with shareholder value.

Acumen Pharmaceuticals CFO Matt Zuga sold a total of 33,266 shares of common stock in two transactions on January 21st and 23rd, 2025, under a pre-arranged 10b5-1 trading plan.

Acumen Pharmaceuticals CEO, Daniel Joseph O'Connell, sold 12,619 shares of common stock to cover tax obligations related to vesting restricted stock units.

Derek M. Meisner, Chief Legal Officer & Corp Sec of Acumen Pharmaceuticals, sold 3,418 shares of common stock to cover tax obligations related to vesting restricted stock units.

Russell Barton, COO of Acumen Pharmaceuticals, sold 2,914 shares of common stock on January 21, 2025, to cover tax obligations related to vesting restricted stock units.

Eric Siemers, Chief Medical Officer of Acumen Pharmaceuticals, sold 3,219 shares of common stock on January 21, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Acumen Pharmaceuticals CEO, Daniel Joseph O'Connell, sold 47,778 shares to cover taxes, received 225,400 restricted stock units, and 338,000 stock options.

Acumen Pharmaceuticals' Chief Regulatory Officer, Amy Schacterle, acquired 8,800 shares of common stock and 13,200 employee stock options on January 6, 2025.

Acumen Pharmaceuticals' President and CDO, James J. Doherty, acquired 62,600 shares of common stock and 93,300 stock options on January 6, 2025.

Acumen Pharmaceuticals' Chief Legal Officer, Derek M. Meisner, sold shares to cover taxes from vested stock and received new stock options and restricted stock units.

Acumen Pharmaceuticals' Chief Operating Officer, Russell Barton, executed multiple stock transactions, including sales to cover tax obligations and the acquisition of restricted stock units and stock options.

Acumen Pharmaceuticals CFO Matt Zuga sold 13,235 shares and acquired 66,800 shares and 100,300 stock options in recent transactions.

Acumen Pharmaceuticals' Chief Medical Officer, Eric Siemers, executed stock transactions including sales to cover taxes and the acquisition of restricted stock units and stock options.

Amy Schacterle, Chief Regulatory Officer of Acumen Pharmaceuticals, acquired 340,000 employee stock options on November 5, 2024, according to a Form 4 filing with the SEC.

RA Capital Management and related entities, including Peter Kolchinsky and Rajeev Shah, report acquisition of stock options in Acumen Pharmaceuticals.

Director Jeffrey L. Ives acquired 25,000 stock options in Acumen Pharmaceuticals on June 10, 2024.

Laura Stoppel, a director of Acumen Pharmaceuticals, acquired stock options for 25,000 shares on June 10, 2024, according to a recent SEC filing.

Director John A. Stalfort III acquired 25,000 stock options in Acumen Pharmaceuticals on June 10, 2024.